Galp Reports Lower Net Profit for First Half

1 Mins read


Galp, the Portuguese energy company, announced its financial results for the first half of the year, revealing a decline in net profit. However, the company remains confident in its full-year guidance despite lower-than-expected commodity prices.

Financial Performance

In the first half of 2023, Galp recorded a net profit of 603 million euros, representing a decrease from the previous year’s first-half figure of 713 million euros. Additionally, the company reported sales of 10.02 billion euros for this period, compared to 12.70 billion euros in the previous year.

During the second quarter, Galp’s earnings before interest, taxes, depreciation, and amortization (EBITDA) on an IFRS basis were 938 million euros, down from 1.55 billion euros in the same period last year. Earnings before interest and taxes (EBIT) on an IFRS basis also declined to 665 million euros from 1.21 billion euros.

Full-Year Guidance

Despite the challenges posed by lower commodity prices, Galp remains confident in its full-year EBITDA guidance. The company attributes this confidence to improved business performance.


Galp’s financial results for the first half of the year reflect a decrease in net profit and sales compared to the previous year. However, the company remains optimistic about its full-year outlook, emphasizing improved business performance as a key factor in maintaining its guidance.

Related posts

Your Social Security Checks are Safe

2 Mins read
Don’t worry, the impending federal government shutdown will not put your monthly Social Security checks in jeopardy. This is certainly a relief…

European Stocks Experience Decrease

1 Mins read
The European stock market saw a decline on Friday, with the Stoxx Europe 600 index finishing down 0.31% at 453.26. Individual Index…

Positive Results for Cancer-Drug Combination in Bladder Cancer Study

1 Mins read
A recent Phase 3 study conducted by Merck & Co., Seagen, and Astellas Pharma has achieved its primary goals in certain patients…

Leave a Reply

Your email address will not be published. Required fields are marked *